Jannsen
Jannsen’s Tremfya becomes first FDA-approved IL-23 inhibitor for active psoriatic arthritis
July 15, 2020Research and Development, Sales and Marketing FDA, Jannsen, Tremfya, active psoriatic arthritis
Janssen has reported that its therapy Tremfya (guselkumab) has become the first selective interleukin (IL)-23 inhibitor approved by the FDA …
Department of Veteran Affairs to offer Janssen’s esketamine to veterans with depression
March 21, 2019Medical Communications Jannsen, Spravato, VA, depression, esketamine, military, veteran affairs
The United States Department of Veteran Affairs (VA), the federal agency responsible for providing healthcare services to military veterans, is …
Top Ten most popular articles on Pharmafile.com this week
October 5, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, Jannsen, NHS, Novartis, Novo Nordisk, dementia, top 10
As September came to a close and October began the UK was hit hard in the headlines after American firm …
Latest content
Long-acting therapies set to reshape HIV treatment market
August 21, 2026
MHRA approves Romvimza for tenosynovial giant cell tumour
August 20, 2026
